Blueprint Medicines Corp. (NASDAQ: BPMC), a global precision therapy provider, has completed its acquisition of Lengo Therapeutics and its lead compound LNG-451, a potential oral precision therapy in development for the treatment of small cell lung cancer. The deal was completed for a price of $250 million in cash with up to $215 million in additional potential milestone payments.
The drug is a potentially best-in-class therapy designed for small cell lung cancer patients with EGFR exon 20 insertion mutations. The investigation new drug application for LNG-451 was submitted to the FDA in December 2021.
“The acquisition of Lengo Therapeutics and its lead candidate LNG-451 enables Blueprint Medicines to expand our pipeline in lung cancer and harness our experience and expertise to advance precision oncology therapies for the patients who need them,” said Fouad Namouni, M.D., president of R&D.